AzurRx Provides Update on MS1819 Phase II Trial
11 avr. 2017 08h00 HE
|
AzurRx BioPharma, Inc.
Initial patient experience shows no safety issues MS1819 appears active, as demonstrated by CFA increases >20% at various dosing levels BROOKLYN, N.Y., April 11, 2017 (GLOBE NEWSWIRE) -- AzurRx...
AzurRx Announces Addition of Charles J Casamento to the Board of Directors
08 mars 2017 09h32 HE
|
AzurRx BioPharma, Inc.
NEW YORK, March 08, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”) a company specializing in the development of non-systemic, recombinant therapies...
AzurRx BioPharma to Present at the 2017 Biotech Showcase Conference
28 déc. 2016 08h00 HE
|
AzurRx BioPharma, Inc.
BROOKLYN, N.Y., Dec. 28, 2016 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc.(NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency
21 déc. 2016 08h00 HE
|
AzurRx BioPharma, Inc.
BROOKLYN, N.Y., Dec. 21, 2016 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
WallachBeth Capital Initiates Research Coverage of AzurRx BioPharma
12 déc. 2016 08h00 HE
|
AzurRx BioPharma, Inc.
BROOKLYN, N.Y., Dec. 12, 2016 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
AzurRx BioPharma Announces Agreement in Principle with TransChem for MTAN Inhibition Technology
06 déc. 2016 08h00 HE
|
AzurRx BioPharma, Inc.
BROOKLYN, N.Y., Dec. 06, 2016 (GLOBE NEWSWIRE) -- AzurRx BioPharma Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
AzurRx CEO Provides Shareholders With a "State of the Union" Communication
01 déc. 2016 08h00 HE
|
AzurRx BioPharma, Inc.
BROOKLYN, N.Y., Dec. 01, 2016 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients
17 nov. 2016 07h45 HE
|
AzurRx BioPharma, Inc.
BROOKLYN, N.Y., Nov. 17, 2016 (GLOBE NEWSWIRE) -- AzurRx BioPharma Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...